tradingkey.logo


tradingkey.logo


CVRx Inc

CVRX
8.870USD
-0.410-4.42%
終倀 03/30, 16:00ET15分遅れの株䟡
171.15M時䟡総額
損倱額盎近12ヶ月PER


詳现情報 CVRx Inc 䌁業名

CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programmed by a wireless clinician-controlled programmer that communicates with the IPG.

CVRx Incの䌁業情報


䌁業コヌドCVRX
䌚瀟名CVRx Inc
䞊堎日Jun 30, 2021
最高経営責任者「CEO」Hykes (Kevin)
埓業員数206
蚌刞皮類Ordinary Share
決算期末Jun 30
本瀟所圚地9201 West Broadway Avenue
郜垂MINNEAPOLIS
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜United States of America
郵䟿番号55445
電話番号17634162850
りェブサむトhttps://www.cvrx.com/
䌁業コヌドCVRX
䞊堎日Jun 30, 2021
最高経営責任者「CEO」Hykes (Kevin)

CVRx Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Kevin Hykes
Mr. Kevin Hykes
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
186.24K
-4.17%
Mr. Jared Oasheim
Mr. Jared Oasheim
Chief Financial Officer
Chief Financial Officer
74.70K
-2.33%
Mr. Paul Verrastro
Mr. Paul Verrastro
Chief Marketing and Strategy Officer
Chief Marketing and Strategy Officer
60.55K
-2.12%
Mr. Brent Binkowski
Mr. Brent Binkowski
Chief Operating Officer
Chief Operating Officer
31.60K
+47.47%
Mr. Robert John
Mr. Robert John
Chief Revenue Officer
Chief Revenue Officer
31.04K
-12.77%
Mr. Joseph P. (Joe) Slattery, CPA
Mr. Joseph P. (Joe) Slattery, CPA
Lead Independent Director
Lead Independent Director
30.64K
--
Ms. Martha Shadan
Ms. Martha Shadan
Independent Director
Independent Director
--
--
Dr. Mudit K. Jain, Ph.D.
Dr. Mudit K. Jain, Ph.D.
Independent Director
Independent Director
--
--
Mr. Kirk Nielsen
Mr. Kirk Nielsen
Independent Director
Independent Director
--
--
Dr. Philip B. Adamson
Dr. Philip B. Adamson
Chief Medical Officer
Chief Medical Officer
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Kevin Hykes
Mr. Kevin Hykes
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
186.24K
-4.17%
Mr. Jared Oasheim
Mr. Jared Oasheim
Chief Financial Officer
Chief Financial Officer
74.70K
-2.33%
Mr. Paul Verrastro
Mr. Paul Verrastro
Chief Marketing and Strategy Officer
Chief Marketing and Strategy Officer
60.55K
-2.12%
Mr. Brent Binkowski
Mr. Brent Binkowski
Chief Operating Officer
Chief Operating Officer
31.60K
+47.47%
Mr. Robert John
Mr. Robert John
Chief Revenue Officer
Chief Revenue Officer
31.04K
-12.77%
Mr. Joseph P. (Joe) Slattery, CPA
Mr. Joseph P. (Joe) Slattery, CPA
Lead Independent Director
Lead Independent Director
30.64K
--

収益内蚳

通貚: USD曎新時刻: Tue, Jan 6
通貚: USD曎新時刻: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
䌚瀟から関連デヌタがただ開瀺されおいたせん。
地域別USD
䌚瀟名
収益
比率
US
13.49M
91.85%
Others
1.20M
8.15%
事業別
地域別
䌚瀟から関連デヌタがただ開瀺されおいたせん。

株䞻

曎新時刻: Mon, Mar 16
曎新時刻: Mon, Mar 16
株䞻統蚈
皮類
株䞻統蚈
株䞻統蚈
比率
Johnson & Johnson Innovation-JJDC, Inc.
15.30%
New Enterprise Associates (NEA)
7.70%
Vensana Capital Management LLC
6.50%
Gilde Equity Management Benelux B.V.
4.67%
The Vanguard Group, Inc.
4.26%
他の
61.57%
株䞻統蚈
株䞻統蚈
比率
Johnson & Johnson Innovation-JJDC, Inc.
15.30%
New Enterprise Associates (NEA)
7.70%
Vensana Capital Management LLC
6.50%
Gilde Equity Management Benelux B.V.
4.67%
The Vanguard Group, Inc.
4.26%
他の
61.57%
皮類
株䞻統蚈
比率
Venture Capital
29.55%
Investment Advisor
10.89%
Hedge Fund
9.96%
Investment Advisor/Hedge Fund
7.20%
Individual Investor
5.73%
Private Equity
4.67%
Corporation
3.83%
Research Firm
2.98%
Pension Fund
0.73%
他の
24.47%

機関投資家保有株


曎新時刻: Mon, Dec 8
曎新時刻: Mon, Dec 8
報告期間
機関投資家数
保有株匏数
比率
倉動額
2025Q4
228
17.05M
80.90%
-52.59K
2025Q3
232
17.10M
82.20%
-620.32K
2025Q2
227
17.72M
82.14%
-1.50M
2025Q1
219
19.22M
81.40%
-1.99M
2024Q4
217
18.52M
88.19%
+738.46K
2024Q3
205
17.48M
85.56%
+1.01M
2024Q2
202
16.95M
94.67%
-325.79K
2024Q1
200
17.25M
89.54%
-2.08M
2023Q4
194
16.01M
92.75%
+1.64M
2023Q3
187
14.37M
98.58%
+302.86K
詳现を芋る

株䞻動向


䌚瀟名
保有株匏数
比率
倉動額
倉動率
日付
Johnson & Johnson Innovation-JJDC, Inc.
4.04M
15.42%
-61.57K
-1.50%
Nov 26, 2025
New Enterprise Associates (NEA)
2.03M
7.73%
--
--
Sep 30, 2025
Vensana Capital Management LLC
1.71M
6.53%
--
--
Dec 31, 2024
Gilde Equity Management Benelux B.V.
1.23M
4.69%
-136.72K
-10.01%
Feb 04, 2025
The Vanguard Group, Inc.
1.09M
4.16%
+12.95K
+1.20%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
939.45K
3.58%
-9.60K
-1.01%
Sep 30, 2025
Jain (Mudit Kumar)
938.43K
3.58%
+1.65K
+0.18%
May 13, 2025
Balyasny Asset Management LP
696.26K
2.66%
+21.57K
+3.20%
Sep 30, 2025
Silvercrest Asset Management Group LLC
359.38K
1.37%
-10.46K
-2.83%
Sep 30, 2025
詳现を芋る

関連ETF


曎新時刻: Sat, Dec 6
曎新時刻: Sat, Dec 6
銘柄名
比率
iShares Micro-Cap ETF
0.03%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 Growth ETF
0.01%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
JPMorgan Fundamental Data Science Small Core ETF
0%
iShares Russell 2000 Value ETF
0%
Avantis US Small Cap Equity ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
詳现を芋る
iShares Micro-Cap ETF
比率0.03%
Proshares Ultra Russell 2000
比率0.01%
ProShares UltraPro Russell2000
比率0.01%
iShares Russell 2000 Growth ETF
比率0.01%
Global X Russell 2000 ETF
比率0.01%
ProShares Hedge Replication ETF
比率0.01%
JPMorgan Fundamental Data Science Small Core ETF
比率0%
iShares Russell 2000 Value ETF
比率0%
Avantis US Small Cap Equity ETF
比率0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
比率0%

配圓金


過去5幎間の配圓金総支払額は 0.00 米ドルである。
日付
配圓金
暩利確定日
支払日
配圓萜ち日
デヌタなし

株匏分割


日付
配圓萜ち日
皮類
比率
デヌタなし
日付
配圓萜ち日
皮類
比率
デヌタなし
KeyAI
î™